Company / Operating Cash Flow
Integra Lifesciences Holdings Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$50.4M
FY2025
5-year range
$50.4M / $312.4M
FY2021-FY2025
Trend
-61.1%
vs FY2024
Sector context
#121 of 164
Health Care
What the data says
At $50M, Integra Lifesciences Holdings's operating cash flow ranks #121 of 164 in the Health Care sector. Operating Cash Flow has declined for 4 consecutive years, from $312M in FY2021 to $50M in FY2025.
Based on SEC 10-K filings.
$50M in FY2025 with a 5-year CAGR of -24.4%.
Declined from $140M to $50M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -42.5%
- 5-Year CAGR
- -24.4%
- 10-Year CAGR
- -
Sector benchmark
#121 of 164 in Health CareTop 74% of 164This company $50.4M Sector average $1.0B
▼
-95.2% below sector average
Key checks
Key Insights
- Integra Lifesciences Holdings's operating cash flow has declined for 4 consecutive years.
- 5-year CAGR of -24.4%, indicating a declining trend.
- In FY2025, operating cash flow decreased 61.1% year-over-year.
- Ranks #121 out of 164 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $50.4M | -61.1% |
| FY2024 | $129.4M | -7.6% |
| FY2023 | $140.0M | -47.1% |
| FY2022 | $264.5M | -15.4% |
| FY2021 | $312.4M | +53.3% |
| FY2020 | $203.8M | -11.9% |
| FY2019 | $231.4M | +15.9% |
| FY2018 | $199.7M | +90.4% |
| FY2017 | $104.9M | +25.5% |
| FY2016 | $83.6M | -20.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026